Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Abstract
Background Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis through ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 gene editing of the erythroid-specific enhancer region of BCL11A in autologous CD34+ hematopoietic stem and progenitor cells (HSPCs). Methods We conducted an open-label, single-group, phase 3 study of exa-cel in patients 12 to 35 years of age with transfusion-dependent β-thalassemia and a β 0 /β 0 , β 0 /β 0 -like, or non–β 0 /β 0 -like genotype. CD34+ HSPCs were edited by means of CRISPR-Cas9 with a guide mRNA. Before the exa-cel infusion, patients underwent myeloablative conditioning with pharmacokinetically dose-adjusted busulfan. The primary end point was transfusion independence, defined as a weighted average hemoglobin level of 9 g per deciliter or higher without red-cell transfusion for at least 12 consecutive months. Total and fetal hemoglobin concentrations and safety were also assessed. Results A total of 52 patients with transfusion-dependent β-thalassemia received exa-cel and were included in this prespecified interim analysis; the median follow-up was 20.4 months (range, 2.1 to 48.1). Neutrophils and platelets engrafted in each patient. Among the 35 patients with sufficient follow-up data for evaluation, transfusion independence occurred in 32 (91%; 95% confidence interval, 77 to 98; P<0.001 against the null hypothesis of a 50% response). During transfusion independence, the mean total hemoglobin level was 13.1 g per deciliter and the mean fetal hemoglobin level was 11.9 g per deciliter, and fetal hemoglobin had a pancellular distribution (≥94% of red cells). The safety profile of exa-cel was generally consistent with that of myeloablative busulfan conditioning and autologous HSPC transplantation. No deaths or cancers occurred. Conclusions Treatment with exa-cel, preceded by myeloablation, resulted in transfusion independence in 91% of patients with transfusion-dependent β-thalassemia. (Supported by Vertex Pharmaceuticals and CRISPR Therapeutics; CLIMB THAL-111 ClinicalTrials.gov number, NCT03655678 .)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
Self-citationBCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., et al. (2015) · Nature · doi:10.1038/nature15521 · Cited by 886
Cao, A., & Galanello, R. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181cd68ed · Cited by 722
An Erythroid Enhancer of BCL11A Subject to Genetic Variation Determines Fetal Hemoglobin Level
Bauer, D. E., Kamran, S. C., Lessard, S., Xu, J., Fujiwara, Y., Lin, C., Shao, Z., Canver, M. C., Smith, E. C., Pinello, L., et al. (2013) · Science · doi:10.1126/science.1242088 · Cited by 653
Origa, R. (2017) · Genetics in Medicine · doi:10.1038/gim.2016.173 · Cited by 509
Exagamglogene Autotemcel for Severe Sickle Cell Disease
Frangoul, H., Locatelli, F., Sharma, A., Bhatia, M., Mapara, M., Molinari, L., Wall, D., Liem, R. I., Telfer, P., Shah, A. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309676 · Cited by 493
Self-citationTaher, A. T., Musallam, K. M., & Cappellini, M. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2021838 · Cited by 477
Self-citationResults of Long-Term Iron-Chelating Therapy
Gabutti, V., & Piga, A. (2009) · Acta Haematologica · doi:10.1159/000203853 · Cited by 378
Corbacioglu, S., Carreras, E., Ansari, M., Balduzzi, A., Cesaro, S., Dalle, J.-H., Dignan, F., Gibson, B., Guengoer, T., Gruhn, B., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.161 · Cited by 363
Self-citationThe switch from fetal to adult hemoglobin.
Sankaran, V. G., & Orkin, S. H. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011643 · Cited by 333
Research works printed but not linked: 1
- Origa R. Beta-thalassemia. In: Adam MP, Mirzaa GM, Pagon RA, et al., eds. GeneReviews. Seattle: University of Washington, 1993.
Cited by
Exagamglogene Autotemcel for Severe Sickle Cell Disease
Frangoul, H., Locatelli, F., Sharma, A., Bhatia, M., Mapara, M., Molinari, L., Wall, D., Liem, R. I., Telfer, P., Shah, A. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309676 · Cited by 493
Self-citationPatient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease
Musunuru, K., Grandinette, S. A., Wang, X., Hudson, T. R., Briseno, K., Berry, A. M., Hacker, J. L., Hsu, A., Silverstein, R. A., Hille, L. T., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2504747 · Cited by 368
The hidden risks of CRISPR/Cas: structural variations and genome integrity
Aussel, C., Cathomen, T., & Fuster‐García, C. (2025) · Nature Communications · doi:10.1038/s41467-025-62606-z · Cited by 89
“Forthe fi rstapprovedCRISPRtherapy, exa-cel, it is well documented that targeting the GATA1 motif in intron 2 of BCL11A suppresses gene expression in an erythroid-speci fi c manner, inducing fetal hemoglobin 58,59 .”
Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A
Srivastava, A., Abraham, A., Aboobacker, F. N., Singh, G., Geevar, T., Kulkarni, U. P., Selvarajan, S., Korula, A., Dave, R. G., Shankar, M., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2410597 · Cited by 60
“Using treosulfan instead of busulfan, as in other myeloablative conditioning protocols for HSC based gene therapy, (18, 22) we show a much-reduced toxicity profile, as is well-known in allogeneic HSC transplant for high-risk cases.”
Kwiatkowski, J. L., Walters, M. C., Hongeng, S., Yannaki, E., Kulozik, A. E., Kunz, J. B., Sauer, M. G., Thrasher, A. J., Thuret, I., Lal, A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01884-1 · Cited by 61
Self-citationGreco, R., Ruggeri, A., McLornan, D. P., Snowden, J. A., Alexander, T., Angelucci, E., Averbuch, D., Bazarbachi, A. A., Hazenberg, M. D., Kałwak, K., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02701-3 · Cited by 78
Gene therapy for genetic diseases: challenges and future directions
Beibei, Q. I. E., Tuo, J., Chen, F., Ding, H., & Lyu, L. (2025) · MedComm · doi:10.1002/mco2.70091 · Cited by 45
Possible opportunities and challenges for traditional Chinese medicine research in 2035
Huang, N., Huang, W., Wu, J., Long, S., Luo, Y., & Huang, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1426300 · Cited by 54
“Arti fi cial intelligence (AI) is accelerating drug discovery (Ren et al., 2024), RNA vaccines offer powerful tools to combat infectious diseases (Andrews et al., 2022), and gene editing techniques such as CRISPR-Cas9 hold immense promise for treating genetic disorders (Locatelli et al., 2024).”
BackgroundSpecificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel
Yen, A., Zappala, Z., Fine, R. S., Majarian, T. D., Sripakdeevong, P., & Altshuler, D. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2313119 · Cited by 35
Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells
Zeng, J., Nguyen, M. A., Liu, P., da Silva, L. F., Levesque, S., Lin, L. Y., Justus, D. G., Petri, K., Clement, K., Porter, S. N., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.11.001 · Cited by 41
Peeling back the layers of immunogenicity in Cas9-based genomic medicine
Stigzelius, V., Cavallo, A. L., Chandode, R. K., & Nitsch, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.045 · Cited by 33
CRISPR-based therapeutic genome editing for inherited blood disorders
Levesque, S., & Bauer, D. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01236-y · Cited by 39
Cappellini, M. D., Viprakasit, V., Georgiev, P., Coates, T. D., Origa, R., Khélif, A., Liew, H.-K., Tantiworawit, A., Chew, L.-P., Khalil, A., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00376-4 · Cited by 30
Self-citationFerraresi, M., Panzieri, D. L., Leoni, S., Cappellini, M. D., Kattamis, A., & Motta, I. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-04900-w · Cited by 38
Self-citationThe epigenetic revolution in hematology: from benchside breakthroughs to clinical transformations
Esfahani, M. A., Servatian, N., Al-Athari, A. J. H., Khafaja, E. S. M., Seraji, H. R., & Samarkhazan, H. S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01783-z · Cited by 24
CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia
Frangoul, H., Hanna, R., Walters, M. C., Kao, R. L., Carroll, C., McManus, M. P., Chang, K., Jaskolka, M. C., Kim, K., Yu, Q., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2501277 · Cited by 23
Self-citationThe deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy
Puzzo, F., & Kay, M. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.041 · Cited by 31
Demirci, S., Zeng, J., Palchaudhuri, R., Wu, C., Abraham, D. M., Hayal, T. B., Essawi, K., Nguyen, M. A., Stasula, U., Chu, R., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.10.014 · Cited by 25
Clinical hematopoietic stem cell-based gene therapy
John, T. D., & Czechowicz, A. D. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.029 · Cited by 34
Give Cas a Chance: An Actionable Path to a Platform for CRISPR Cures
Urnov, F. D. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0082 · Cited by 21
Petri, K., D’Ippolito, E., Künkele, A., Koehl, U., Busch, D. H., Einsele, H., & Hudecek, M. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01072-4 · Cited by 36
Gene therapy for β-thalassemia: current and future options
Hardouin, G., Miccio, A., & Brusson, M. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.12.001 · Cited by 23
Diamantidis, M. D., Ikonomou, G., Argyrakouli, I., Pantelidou, D., & Delicou, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211886 · Cited by 25
“Table 2 shows the gene addition or gene editing therapeutic strategies for hemoglobino pathies and describes the mechanism of action and the relevant technology and cost, providing information of the date of FDA and EMA approval [171,172,180,186].”
Janoudi, T., Jagdale, M., Wu, M., Gorlla, S., Zhang, P., Shao, Y., Li, L., Bowley, S. R., Marco, E., & Chang, K.-H. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014040 · Cited by 21
“8 These studies validate the safety and effectiveness of this approach and supported the approval of exa-gamglogene autotemcel for treating SCD and TDT, with long-term studies ongoing.”
Recent advancements in gene therapy for sickle cell disease and β-thalassemia
Li, L., & Mandal, P. K. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1468952 · Cited by 29
Mirza, A., Ritsert, M.-L., Tao, G., Thakar, H. L., Lobitz, S., Heine, S., Koscher, L., Dürken, M., Schmitt, A., Schmitt, M. W., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014104 · Cited by 18
The Fetal-to-Adult Hemoglobin Switch — Mechanism and Therapy
Orkin, S. H. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2405260 · Cited by 21
Engineering adeno-associated viral vectors for CRISPR/Cas based in vivo therapeutic genome editing
Moyo, B., Brown, L. B. C., Khondaker, I., & Bao, G. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123314 · Cited by 13
Clinical application of base editing for treating β-thalassaemia
Lai, Y., Liu, R., Wang, L., Ma, X.-K., Li, Y., Yang, G., Shi, L., Guo, Y., Wei, Z., Zhou, X., et al. (2026) · Nature · doi:10.1038/s41586-026-10342-9 · Cited by 22
Monitoring biological effects of somatic cell genome editing
Freedman, B., Bulte, J. W. M., Conklin, B. R., Judge, L. M., Dwinell, M. R., Geurts, A. M., Sitton, M. J., Mahajan, V., Kiani, S., Gersbach, C. A., et al. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-025-00916-0 · Cited by 16
Dipalo, L. L., Mikkelsen, J. G., Gijsbers, R., & Carlon, M. S. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.258 · Cited by 12
Inhibiting ferroptosis enhances ex vivo expansion of human haematopoietic stem cells
della Volpe, L., Lee, A. J., Antoszewski, M., Deik, A., Safina, K. R., Gao, T., Guo, C., Ye, T., Lyu, P., Martin-Rufino, J. D., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01814-7 · Cited by 19
Musallam, K. M., Sheth, S., Cappellini, M. D., Shah, F., Rivella, S., Sankaran, V. G., Kuo, K. H. M., Viprakasit, V., Eleftheriou, A., Angastiniotis, M., et al. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00320-5 · Cited by 11
Self-citationExa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease
Frangoul, H., de la Fuente, J., Chopra, Y. R., Meisel, R., Amrolia, P. J., Algeri, M., Sharma, A., Cappellini, M. D., Corbacioglu, S., Kattamis, A., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2603387 · Cited by 12
Self-citationKelkar, A. H., Achebe, M., & Hantel, A. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016053 · Cited by 13
Tian, Z., Wang, X., Chatterjee, S., Miller, W., Guerrero, E. D., Sung, Y., Benitez, A. P., Dilliard, S. A., Bian, X., Vaidya, A., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01615-9 · Cited by 14
Treating genetic blood disorders in the era of CRISPR-mediated genome editing
Almotiri, A., Abogosh, A., Abdelfattah, A., Alowaisy, D., & Rodrigues, N. P. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.031 · Cited by 16
Habara, A. H. (2025) · Cells · doi:10.3390/cells14040312 · Cited by 9
Grzechnik, P., & Mischo, H. E. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168802 · Cited by 11
Babu, P., Azhagiri, M. K. K., Venkatesan, V., Magis, W., Prasad, K. M., Suresh, S., Pai, A. A., Marepally, S. K., Srivastava, A., Mohankumar, K. M., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04117-0 · Cited by 9
Intracellular Delivery Enabled by Squeezing Mechanoporation
Zhang, G., Mu, R., Ma, Y., & Li, B. (2025) · Small Methods · doi:10.1002/smtd.202500338 · Cited by 9
CRISPR/Cas9 for achieving postintervention HIV control
Moso, M. A., Roche, M., Cevaal, P. M., & Lewin, S. R. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000963 · Cited by 13
Multiplex base editing of BCL11A regulatory elements to treat sickle cell disease
Fontana, L., Martinucci, P., Amistadi, S., Félix, T., Mombled, M., Tachtsidi, A., Corre, G., Chalumeau, A., Hardouin, G., Martin, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102376 · Cited by 15
Gene therapy for sickle cell disease and thalassemia
Scaramellini, N., Panzieri, D. L., & Cappellini, M. D. (2025) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000867 · Cited by 11
Self-citationRecent Progress in Gene Delivery Systems Based on Gemini‐Surfactant
Qian, P., Chen, Y., Xing, Y., Wu, K., Zhang, Q., & Chen, H. (2025) · MedComm – Future Medicine · doi:10.1002/mef2.70027 · Cited by 8
de la Fuente, J., Frangoul, H., Lang, P., Wall, D. A., Meisel, R., Corbacioglu, S., Li, A. M., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016702 · Cited by 12
“16 17-19 In a prespecified interim analysis of the pivotal phase 3 CLIMB THAL-111 trial, a single infusion of exa-cel increased mean HbF levels to 11.9 g/dL, eliminating the need for RBC transfusions in 91% of participants with TDT, the primary end point of the study, with a safety profile consistent with the myeloabl…”
InfluentialSelf-citationSingle–amino acid variants in target epitopes can confer resistance to antibody-based therapies
Marone, R., Asllanaj, E., Capoferri, G., Schwede, T. F., Jeker, L. T., & Lepore, R. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ady4877 · Cited by 12
Corbacioglu, S., Bajwa, R. P. S., Antmen, B., Balduzzi, A., Boelens, J. J., Bonifazi, F., Cesaro, S., Ciceri, F., Colecchia, A., Dignan, F. L., et al. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02793-x · Cited by 7
“Despite careful PK monitoring, the incidences of SOS/VOD reached surprisingly high rates of 12.5% and 9,3% in the editing and gene addition trials, respectively [5, 80].”
InfluentialSelf-citationTHERAPEUTIC GENE EDITING FOR HEMOGLOBINOPATHIES
Testa, U., Leone, G., & Cappellini, M. D. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.068 · Cited by 9
Self-citationOriga, R., & Issa, L. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226966 · Cited by 13
“15 of 23 Quality-of-life (QOL) measures showed clinically signi fi cant improvements [127]. discontinued transfusions after 21.6 and 12.2 months and have been transfusion-free for 8.0 and 12.2 months, respectively, and one stopped transfusion after 14.5 months, as of 18 September 2023.”
InfluentialA clinical roadmap for base and prime editing
Flugel, C., Cadiñanos-Garai, A., & Abou‐El‐Enein, M. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00360-z · Cited by 6
Hmaidan, S., Heertum, K. V., Bhatia, S., Domm, J., McManus, M. P., Carroll, C., Stults, A., Bruce, K., Evans, M. D., & Frangoul, H. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.08.004 · Cited by 5
Self-citationLandscape of ex vivo gene therapies: Technological trends and future prospects
Almeida-Oliveira, A., Bonamino, M., Simões, M., Martins, V. H. V., Freire, D. P. B., Danowski, A., Catão, T. P., Varela, J. D. N. E. S., Mazzi, M. T., Gottgtroy, C., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101580 · Cited by 6
Nonclinical evaluation of renizgamglogene autogedtemcel for SCD and TDT
Marco, E., Sousa, P., Janoudi, T., Dreuzy, E. D., Heath, J. M., Viswanathan, R., Zuris, J. A., Gotta, G. M., Giannoukos, G., Hansen, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.031 · Cited by 9
Advances in β-Thalassemia Gene Therapy: CRISPR/Cas Systems and Delivery Innovations
Liu, H., & Zhang, P. (2025) · Cells · doi:10.3390/cells14201595 · Cited by 11
“The safety profile was consistent with that of standard busulfan conditioning and autologous transplantation, with no treatment-related deaths or malignancies reported [94].”
RNA-based drugs: current, imminent and possible therapeutic applications
Torrisi, S. A., Geraci, F., Diolosà, L., Luca, A. D., Falzone, L., Drago, F., Libra, M., & Leggio, G. M. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108958 · Cited by 11
Chakraborty, C., Bhattacharya, M., Das, A., Agoramoorthy, G., & Lee, S.-S. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102859 · Cited by 12
Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement
Ambardekar, A. V., Bhatt, A., Hoekstra, M., Kelly, M., Musunuru, K., & Natarajan, P. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5092 · Cited by 13
CRISPR–Cas9 Therapeutics in Early Clinical Development: Delivery and Molecular Diagnostics
Rutkowska, A., Strózik, T., Wasiak, T., Ciunowicz, D., Kapelan, N., Szczepaniak, N., Sosnowski, J., Goślińska, W., Bartkowiak, J., Budny-Lewandowska, A., et al. (2026) · Cells · doi:10.3390/cells15070644 · Cited by 5
Verheul, T. C. J., Gillemans, N., Putzker, K., Majied, R., Li, T., Vasiliou, M., Eussen, B., de Klein, A., van IJcken, W. F. J., van den Akker, E., et al. (2024) · HemaSphere · doi:10.1002/hem3.139 · Cited by 6
Hemoglobinopathies in the Neonate
Blankenhorn, K., & Strumph, K. L. (2024) · NeoReviews · doi:10.1542/neo.25-11-e720 · Cited by 7
Sharma, A., & John, T. D. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015413 · Cited by 5
Epigenetic Regulation of Erythropoiesis: From Developmental Programs to Therapeutic Targets
Vasiloudis, N.-I., Paschoudi, K., Beta, C., Georgolopoulos, G., & Psatha, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136342 · Cited by 9
“…in sustained normal Hb levels 12.5 ± 1.8 g /dl for SCD and 13.1 ± 1.4 g /dl for beta-thalassemia patients After the gene therapy, the 91% of the thalassemic patients were transfusion independent and the 97% of the SCD had reduced vaso-occlusive crisis for a period of 12 months or more [217–219].”
InfluentialPrecision T cell correction platform for inborn errors of immunity
Mamia, K., Kolbeinsdóttir, S., Labun, K., Li, Z., Komisarczuk, A. Z., Keskitalo, S., Reint, G., Haugen, F. L., Lindestad, B. O., Jensen, S. S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.018 · Cited by 5
Tang, Y., Zou, J., Li, Q., Liu, Y., Guo, X. D., Bai, H., He, X. D., Gan, C., Zhao, X., Wu, W., et al. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126189 · Cited by 8
CRISPR-epigenetic crosstalk: From bidirectional regulation to therapeutic potential
Wei, Y., Sun, J. Y., & Zhu, R. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.10.031 · Cited by 7
Targeting LncRNAs with CRISPR/Cas9 for Kidney Therapeutics: A Review
Puri, B., & Gaikwad, A. B. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149932 · Cited by 4
Canarutto, D., Fiumara, M., Venkatesan, V., Gaddoni, C., Shiroshita, K., Varesi, A., Albano, L., Pelosi, G., Silva, A., Firrito, C., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03142-z · Cited by 6
Handgretinger, R., & Mezger, M. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2399134 · Cited by 9
Self-citationThe genetic and molecular basis of a connexin-linked skin disease
Lucaciu, S. A., & Laird, D. W. (2024) · Biochemical Journal · doi:10.1042/bcj20240374 · Cited by 4
Felder, A.-K., Tjalsma, S. J. D., Verhagen, H. J. M. P., Majied, R., Verstegen, M. J. A. M., Verheul, T. C. J., van Haren, J., Mohnani, R., Gremmen, R., Krijger, P. H. L., et al. (2025) · Blood · doi:10.1182/blood.2024028128 · Cited by 8
A new breakthrough in genome editing: the story of Casgevy
Olalla-Sastre, B., & Rı́o, P. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.06.003 · Cited by 4
In cellulo DNA assembly for targeted genomic integration and rearrangement in human cellsPreprint
Levesque, S., Kawashima, N., Hwang, G., Becerra, B., Schoonenberg, V. A. C., Mannherz, W. P., Homfeldt, L., Pinello, L., Agarwal, S., & Bauer, D. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.16.659926 · Cited by 4
Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel — Update
Yen, A., Boitano, T., Zappala, Z., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2503294 · Cited by 3
Arcioni, F., Bonetti, M., Sau, A., Zecca, M., Alzahrani, M., Alahmari, B., Alsadi, H. M., Almozaini, A., Ahmed, M., Essa, M., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.70167 · Cited by 6
Liu, S., Chen, Y., Li, Y., Qian, L., Dong, G., Zhang, Q., Zhou, X., Guo, H., Sun, H., Lin, Q., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.017 · Cited by 4
Lei, L., Kaufmann, M. M., Lao, J., Thoulass, G., Ammann, S., Xiao, H., Rhiel, M., Dettmer‐Monaco, V., Grünewald, J., Andrieux, G., et al. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.04.014 · Cited by 6
Chalumeau, A., Antoniou, P., Dames, M. B., Martinucci, P., Retana, E., Gupta, P., Firth, M. A., Reddivari, M., Chandran, A. S., Yen, J. S., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102974 · Cited by 4
Applications of genome editing technologies in the treatment of human diseases
Alshorman, J., Mehran, M. J., Tembo, K. M., Mostafavi, N., Bolideei, M., & Wang, Y. L. (2026) · Gene Therapy · doi:10.1038/s41434-026-00627-z · Cited by 4
Cappellini, M. D., Sheth, S., Taher, A. T., Al-Samkari, H. T., Antmen, B., Benéitez, D., Cannas, G., Coates, T. D., Czapla, L., Dahlin, J. L., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00874-3 · Cited by 4
Self-citationGibson, N. M., Elgarten, C. W., Oved, J. H., Wray, L., Freedman, J. L., Khandros, E., Worster, E., Nicholas, P., Kadauke, S., Wang, Y., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.06.029 · Cited by 4
Self-citationBeyond transfusions and transplants: genomic innovations rewriting the narrative of thalassemia
Shi, L., Yan, X., Xia, Y., Zhao, Y., Zhu, X., Li, Q., & Xu, Z. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06548-y · Cited by 8
Extending Gene Medicines to All in Need
McCune, J. M., & Kiem, H. (2024) · New England Journal of Medicine · doi:10.1056/nejme2403104 · Cited by 4
Challenges and Outlooks in Precision Medicine: Expectations Versus Reality
Yan, R. E., & Greenfield, J. P. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.06.142 · Cited by 4
Role of B-Cell Lymphoma/Leukemia 11A in Normal and Malignant Hematopoiesis
Zhang, H., Zeng, J., Zhang, F., Liu, J., & Liang, L. (2025) · Biology · doi:10.3390/biology14010026 · Cited by 5
Felder, A.-K., Tjalsma, S. J. D., Verhagen, H. J. M. P., Majied, R., Verstegen, M. J. A. M., Verheul, T. C. J., Mohnani, R., Gremmen, R., Krijger, P. H. L., Philipsen, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.13.632719 · Cited by 3
Impact of Human Genetic Variation Underlying Resistance to Antigen-Specific ImmunotherapyPreprint
Marone, R., Asllanaj, E., Capoferri, G., Schwede, T. F., Jeker, L. T., & Lepore, R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.02.651174 · Cited by 3
The Coming of Age of Gene Therapy for the Treatment of Human Diseases: A Regulatory Perspective
Rodríguez, L., de Felipe, P., Martín, R., Martínez, J., Ordóñez, D., Rojo, S., Martínez, J. F., Rincón, E., Cejalvo, T., Izquierdo, I., et al. (2025) · Human Gene Therapy · doi:10.1177/10430342251372047 · Cited by 2
Direct and indirect regulation of fetal globin transcript by the RNA-binding protein IGF2BP1
Coyne, S. M., Hwang, G.-H., Wu, T., Hossain, M. A., Vinjamur, D. S., Starrs, M. M., Zeng, J., Andresen, F., Gutierrez, A. M., Shimamura, A., et al. (2026) · Blood · doi:10.1182/blood.2025031840 · Cited by 5
The ENERGIZE trial: Is mitapivat ready to take center stage in NTDT management?
Algeri, M., & Locatelli, F. (2025) · Med · doi:10.1016/j.medj.2025.100844 · Cited by 2
Self-citationAprile, A., Lidonnici, M. R., & Ferrari, G. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102419 · Cited by 7
Base editing of β 0 -thalassemia mutations as a therapeutic strategy for severe β-hemoglobinopathies
Hardouin, G., Martinucci, P., Scaramuzza, S., Antoniou, P., Corradi, F., Tachtsidi, A., Corre, G., Mombled, M., Chermont, J., Manceau, S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adt8617 · Cited by 4
Advances in Gene Therapy for Inherited Haemoglobinopathies
Gaspar, A. B., & Gaspar, H. B. (2025) · Hematology Reports · doi:10.3390/hematolrep18010004 · Cited by 4
“The safety profile of the treatment was consistent with that of busulfan conditioning and autologous transplant, and there was no evidence of oncogenesis or clonal proliferation [34].”
Gene Therapy–Related Malignancy and the Risk of Cancer Exceptionalism
Benedetti, D. J., Marron, J. M., & Kodish, E. D. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-01844 · Cited by 2
Current research status of third-generation sequencing technology in thalassemia detection
Zhu, F., Lai, Y., & He, S. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1705599 · Cited by 2
CRISPR in Medicine: A Systematic Review of Clinical Trials and Therapeutic Applications
Rahmanian, M., Khoshandam, M., Mousazadeh, M., Yang, P., Soltaninejad, H., Dehkordi, P. K., Sadeghizadeh, M., Goudarzi, M. T. H., Azimi, A. H., & Sheykhhasan, M. (2026) · Human Gene Therapy · doi:10.1177/10430342251409714 · Cited by 8
Testa, U., Castelli, G., & Pelosi, E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041379 · Cited by 4
“…β -thalassemic patients, showing that 91% of these patients become transfusion-independent after gene therapy, with a mean Hb level of 13.1 g/dL and a mean HbF level of 11.9 g/dL; 9% of the treated patients did not reach transfusion independence but markedly decreased their transfusion needs [174].”
InfluentialCalcium Shock Enables Efficient and Programmable Particle Delivery for Genome Editing Applications
Vo, N., de Oñate, L., Frank, M., Hu, X., Blackburn, S. M., Foss, D. V., Villegas, J., Asija, K., Hockemeyer, D. F., Fu, H., et al. (2026) · Advanced Science · doi:10.1002/advs.202510441 · Cited by 2
Broad-acting antivirals: the pursuit of pan-viral therapeutics in the era of pandemics
Олеговна, Б. Е., Kostyushev, D. S., Tikhonov, A., Chulanov, V. P., & Gordeychuk, I. V. (2026) · Journal of Virology · doi:10.1128/jvi.00077-26 · Cited by 3
More Options for Gene Editing in Hemoglobinopathies
Locatelli, F. (2026) · New England Journal of Medicine · doi:10.1056/nejme2602194 · Cited by 2
Self-citation
Metadata
- Authors
- Locatelli, F., Lang, P., Wall, D., Meisel, R., Corbacioglu, S., Li, A. M., de la Fuente, J., Shah, A. J., Carpenter, B., Kwiatkowski, J. L., Mapara, M., Liem, R. I., Cappellini, M. D., Algeri, M., Kattamis, A., Sheth, S., Grupp, S., Handgretinger, R., Kohli, P., Shi, D., Ross, L., Bobruff, Y., Simard, C., Zhang, L., Morrow, P. K., Hobbs, W. E., & Frangoul, H.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- From IRCCS Ospedale Pediatrico Bambino Gesù (F.L., M.A.) and Catholic University of the Sacred Heart (F.L.), Rome, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan (M.D.C.), and the Department of Health Sciences, Magna Graecia University, Catanzaro (M.A.) — all in Italy; University Children’s Hospital Tübingen (R.H.), and the Cluster of Excellence iFIT (EXC 2180) “Image-guided and Functionally Instructed Tumor Therapies” and the German Cancer Consortium, Partner Site Tübingen, University of Tübingen (P.L.), Tübingen, the Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf (R.M.), and the University of Regensburg, Regensburg (S.C.) — all in Germany; the Hospital for Sick Children and University of Toronto, Toronto (D.W.), and BC Children’s Hospital, University of British Columbia, Vancouver (A.M.L.) — all in Canada; Imperial College Healthcare NHS Trust, St. Mary’s Hospital (J.F...
- ORCID
- Locatelli, Franco
- Lang, Peter
- Wall, Donna
- Meisel, Roland
- Corbacioglu, Selim
- Li, Amanda M.
- Shah, Ami J.
- Carpenter, Ben
- Kwiatkowski, Janet L.
- Mapara, Markus
- Liem, Robert I.
- Cappellini, Maria Domenica
- Algeri, Mattia
- Kattamis, Antonis
- Sheth, Sujit
- Grupp, Stephan
- Handgretinger, Rupert
- Kohli, Puja
- Zhang, Lanju
- Morrow, Phuong Khanh
- Frangoul, Haydar
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-05-09
- Volume
- 390
- Issue
- 18
- Pages
- 1663-1676
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4395068362
- Cited by
- 253
- References
- 35
- Citations by year
- 2026: 128 · 2025: 89 · 2024: 35
- FWCI
- 70.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- CRISPR Therapeutics
- Vertex Pharmaceuticals
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- exagamglogene autotemcel, beta-thalassemia, CRISPR/Cas9 genome editing, BCL11A, fetal hemoglobin, hematopoietic stem cell transplantation, myeloablative conditioning, busulfan, transfusion independence, non-viral gene therapy, autologous hematopoietic stem cells
- MeSH terms
- Gene Editing, Adolescent, Adult, Blood Transfusion, Busulfan, Child, Europe, Female, Fetal Hemoglobin, Hematopoietic Stem Cells, Humans, Male, North America, Repressor Proteins, Transplantation, Autologous, beta-Thalassemia, Hematopoietic Stem Cell Transplantation, Antigens, CD34, Transplantation Conditioning, Myeloablative Agonists, Young Adult, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.